glp-1 dosing schedule Administration and of GLP1 receptor agonists and dual Small dose, big difference ✨

Obesity is also a leading driver of gastrointestinal (GI) and hepatobiliary cancers, from colorectal cancer to hepatocellular carcinoma, making any therapy that modifies obesity-related cancer risk directly relevant to gastroenterology practice

doi: 10.1016/j.wjorl.2018.02.006

GLP-1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Zepbound, initially developed for diabetes management, show promising potential in treating psoriasis and psoriatic arthritis (PsA)

Two new studies led by researchers at the University of Chicago found that although GLP-1 drugs deliver impressive long-term health improvements, their current prices far exceed accepted thresholds for cost-effectiveness, posing difficult choices for policymakers, insurers and patients

Promotional pricing varies